TRDA
Entrada Therapeutics Inc
NASDAQ: TRDA · HEALTHCARE · BIOTECHNOLOGY
$14.50
+7.41% today
Updated 2026-05-01
Market cap
$503.12M
P/E ratio
—
P/S ratio
19.79x
EPS (TTM)
$-3.47
Dividend yield
—
52W range
$5 – $14
Volume
0.2M
Entrada Therapeutics Inc (TRDA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-10.80M | $-25.57M | $-50.86M | $-93.79M | $139.80M | $-41.56M | $-128.51M |
| Capital expenditures | $630000.00 | $2.32M | $4.58M | $2.89M | $5.61M | $3.16M | $1.04M |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $294000.00 | $325000.00 | $2.53M | $9.89M | $13.11M | $17.91M | $19.61M |
| Free cash flow | $-11.43M | $-27.89M | $-55.44M | $-96.67M | $134.19M | $-44.72M | $-129.55M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $252.02M | — | — | — | — |